No abstract

No abstract

No abstract

Medetomidine is most potent á-2 adrenergic selective agonist, produces consistent sedation, anxiolysis and muscle relaxation, which makes it a popular sedative agent in veterinary anaesthesia. It produces dose dependent sedation and analgesia in animals. In veterinary practice it is used for premedication and as an adjunct to general anaesthesia in several species. Similar to other alpha-2 agonists it exerts its effect through the action on alpha-2 adrenergic receptors. The sedative and anxiolytic effects of á-2 agonists are mediated by agonism of supraspinal autoreceptors situated in the pons, whereas analgesic effects are mediated by agonism of heteroreceptors located in the dorsal horn of the spinal cord. Medetomidine through stimulation of central and peripheral adrenoreceptors, significantly affect cardiovascular function. Medetomidine reduces both rate and depth of respiration. Medetomidine generally used along with butorphanol for premedication prior to induction of general anaesthesia. Medetomidine administration reduces both injectable and inhalant anesthetic requirements in several species.

Background: Cerebral venous thrombosis (CVT) is any thrombosis occurring in intracranial veins and sinuses, which is a rare disorder affecting 5 persons per million per year with huge regional variation. Pregnancy and puerperium are the most prevalent prothrombotic states leading to cerebral venous thrombosis. The objective of this study was to analysis the clinical profile of CVT in pregnancy and puerperium.Methods: In this prospective study, we analysed 52 consecutive patients admitted with impairment of consciousness, seizures or focal neurological deficit at our hospital. The diagnosis of CVT was confirmed by neuroimaging. Detailed history, clinical examination and laboratory investigations were carried out in all the cases and analysed.Results: The incidence of CVT associated with pregnancy and puerperium at our Hospital was 3.9 per 1000 obstetric admissions. The age of the patients varied from 18-35 years with a maximum age incidence (77%) in the III decade (21-30 years). The maximum incidence was during the first two weeks of puerperium (61.8%). The most common presenting symptoms were focal or generalised seizures (88.4%) followed by headache (65.3%). In spite of the alarming clinical picture, recovery was rapid and remarkable. Total mortality was 15.5% (8 cases).Conclusions: CVT is more common during the puerperium than in the antenatal period. Obstetric CVT has a more acute onset with excellent recovery when promptly diagnosed and treated.